Vignola Mark J. 4
4 · Terns Pharmaceuticals, Inc. · Filed Jan 6, 2025
Insider Transaction Report
Form 4
Vignola Mark J.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-01-02$5.72/sh−8,129$46,524→ 83,811 total - Sale
Common Stock
2025-01-06$5.80/sh−9,059$52,500→ 74,752 total
Footnotes (4)
- [F1]Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
- [F2]This sale price represents the weighted average sale price of the shares sold ranging from $5.64 to $5.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
- [F4]This sale price represents the weighted average sale price of the shares sold ranging from $5.66 to $5.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.